- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00548652
Role of Apathy in the Effectiveness of Weight Loss Interventions
Role of Apathy in the Effectiveness of Weight Loss Interventions in Obese Patients
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
Title: The role of Apathy in the effectiveness of weight loss interventions in obese patients
Objective: Obesity is a major public health problem. Apathy is a common behavioral problem characterized by loss of initiative, poor motivation and persistence. Presence of apathy impairs the self-care behavior in obese patients. Lack of novelty might impair a patient's ability to seek new interactions, life styles and new treatment options for obesity. Lack of motivation might impair a patient's ability to initiate exercise regimen or diet whereas lack of persistence impairs the compliance with these regimens. Thus, apathy influences all stages of self-care. We hypothesize that the treatment of apathy will result in better adherence to weight loss interventions in obese veterans enrolled in the MOVE program.
Research Design: A prospective open label randomized study. Group 1 will have patients with obesity as defined as BMI>30, and apathy defined as AES score of > 40. This group will be treated with standard nutrition counseling. Group 2 will have patients with obesity and apathy as defined above and will receive the MOVE enhancement program alone (The MOVE program is a national VA weight loss program). Group 3 will be treated with methylphenidate along with the MOVE enhancement program. Group 4 will be treated with medical crisis counseling along with the MOVE enhancement program. Group 5 will be treated with methylphenidate, and the medical crisis counseling along with the MOVE enhancement program.
Methodology: 30 patients meeting the criteria will be enrolled in each of the five arms. All patients will be in the study for duration of six months. All patients in the methylphenidate arm will be started at 5mg twice daily and titrated to 10mg twice daily at two weeks. Patients will be assessed on regular intervals using the Apathy Evaluation Scale, Hamilton Depression Scale and the Patient activation measure. MOVE sessions will be held once weekly from the 2nd visit to the end of the study. Medical Crisis Counseling visits will be every week for nine sessions and then every other week till the end of the study
Clinical Relationships/Significance: The prevalence of obesity in the general population is over 30%. However the prevalence of obesity in the VA health system is almost 70%. Since obesity predisposes to several co-morbid conditions such as hypertension, diabetes and cardiovascular disease, it is important to develop interventions that are effective in inducing weight loss. Since apathy plays a large role in the self care behaviours that lead to obesity, treating apathy may improve adherence to weight loss programs
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Nebraska
-
Omaha, Nebraska, Forente stater, 68105-1873
- VA Medical Center, Omaha
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- BMI >30
- Apathy score >40
Exclusion Criteria:
- History of cancer, except basal cell
- Cardiovascular event in last 6 months
- Renal failure
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Ingen inngripen: 1
standard nutrition counselling
|
|
|
Eksperimentell: 2
MOVE -weight loss intervention
|
is a VA based multidesciplinary weight loss intervention
|
|
Eksperimentell: 3
MOVE plus medical crisis counselling
|
is a VA based multidesciplinary weight loss intervention
group counselling sessions
|
|
Eksperimentell: 4
MOVE plus methylphenidate
|
is a VA based multidesciplinary weight loss intervention
methyphenidate will be used to treat apathy dose 10mg bid
|
|
Eksperimentell: 5
MOVE plus methyphenidate plus medical crisis counselling
|
is a VA based multidesciplinary weight loss intervention
group counselling sessions
methyphenidate will be used to treat apathy dose 10mg bid
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Apathy Evaluation Scale
Tidsramme: 6 months
|
Apathy Evaluation Scale (AES) measures apathy over the previous four weeks Scale range: 18 (minimum score)- 72 (Maximum score) Higher scores indicate higher apathy Better outcome would be reduction in the score
|
6 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Weight
Tidsramme: 6 months
|
value at 6 months minus value at baseline
|
6 months
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Cyrus DeSouza, MD, VA Medical Center, Omaha
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 00469
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på MOVE
-
University of California, San FranciscoFullførtKardiovaskulære sykdommer | Iskemisk hjertesykdom | Ustabil angina | Systolisk hjertesviktForente stater
-
University of California, San FranciscoTilbaketrukket
-
University GhentResearch Foundation Flanders; Agentschap Zorg en Gezondheid, Belgium; Vlaams...FullførtDepressive symptomer | Velvære | Livsstil, sunn | MotstandsdyktighetBelgia
-
Johns Hopkins Bloomberg School of Public HealthAminu Kano Teaching Hospital; Postgraduate Institute of Medical Education...Fullført
-
Merck Sharp & Dohme LLCFullførtNedsatt leverfunksjonForente stater
-
Merck Sharp & Dohme LLCFullførtNedsatt nyrefunksjonForente stater
-
Merck Sharp & Dohme LLCFullført
-
National Cancer Institute (NCI)FullførtEggstokkreftForente stater